Holen Sie sich die Stockscreener-App
4.105
1.20%
-0.055
Schlusskurs vom Vortag:
$4.16
Offen:
$4.15
24-Stunden-Volumen:
355.06K
Relative Volume:
0.28
Marktkapitalisierung:
$788.84M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-74.39M
KGV:
-9.3295
EPS:
-0.44
Netto-Cashflow:
$-78.92M
1W Leistung:
+1.23%
1M Leistung:
-12.18%
6M Leistung:
+27.24%
1J Leistung:
+23.05%
1-Tages-Spanne:
$4.08
$4.225
1-Wochen-Bereich:
$3.92
$4.33
52-Wochen-Spanne:
$2.705
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Firmenname
Arbutus Biopharma Corp
Sektor
Branche
Telefon
604-419-3200
Adresse
701 VETERANS CIRCLE, WARMINSTER, PA
Vergleichen Sie ABUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.1016 | 800.07M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-02-02 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Eingeleitet | Jefferies | Hold |
| 2020-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-27 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-07-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-06 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | Bestätigt | B. Riley FBR | Buy |
| 2019-10-04 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | Hochstufung | Wedbush | Underperform → Neutral |
| 2018-10-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-06 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2018-03-19 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | Bestätigt | Wedbush | Outperform |
| 2016-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
Alle ansehen
Arbutus Biopharma Corp Aktie (ABUS) Neueste Nachrichten
Aug Closing: Should I buy Arbutus Biopharma Corporation stock nowJuly 2025 Volume & Weekly High Momentum Picks - baoquankhu1.vn
Arbutus Biopharma (ABUS) Patent Invalidated by European Patent O - GuruFocus
Arbutus Biopharma (ABUS) Faces Patent Revocation in Europe - GuruFocus
ABUS Stock Tumbles on European Patent Revocation - StocksToTrade
Arbutus Biopharma (ABUS) Shares Drop Amid Patent Revocation - GuruFocus
Market Dynamics Cause Shifts for Arbutus Biopharma - StocksToTrade
Arbutus Biopharma (ABUS) Patent Revocation Leads to 18% Stock Crash - Intellectia AI
Arbutus Biopharma (NASDAQ:ABUS) Shares Gap DownHere's Why - MarketBeat
Arbutus (ABUS) upgraded to buy: Here's what you should know - MSN
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Arbutus Biopharma Shares Fall 19% On European Patent Revocation - Nasdaq
Arbutus Biopharma (ABUS) Patent Revocation Leads to 14% Pre-Market Drop - Intellectia AI
European Patent Office revokes Arbutus Biopharma patent following appeal - Investing.com
Arbutus Biopharma CorpEPO revokes Arbutus Biopharma's European patent EP 2279254SEC filing - marketscreener.com
ABUS Stock Price, Forecast & Analysis | ARBUTUS BIOPHARMA CORP (NASDAQ:ABUS) - Chartmill
Weekly Trades: Will Arbutus Biopharma Corporation stock gain from lower inflationTrade Signal Summary & Stock Market Timing Techniques - Bộ Nội Vụ
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
How sustainable is Arbutus Biopharma Corporation stock dividend payoutBear Alert & Safe Entry Momentum Stock Tips - Улправда
Why Arbutus Biopharma Corporation stock is popular among millennialsQuarterly Portfolio Summary & Long-Term Growth Plans - Улправда
New Highs: Why Arbutus Biopharma Corporation stock is popular among millennialsEarnings Miss & Growth-Oriented Investment Plans - Улправда
What is the fair value of Arbutus Biopharma Corporation stock nowWeekly Trading Summary & Weekly Momentum Picks - Улправда
Will Arbutus Biopharma Corporation stock deliver shareholder valueWeekly Market Report & Fast Entry Momentum Alerts - Улправда
How Arbutus Biopharma Corporation stock reacts to Fed rate cutsQuarterly Portfolio Summary & Weekly High Momentum Picks - Улправда
Is Arbutus Biopharma Corporation stock supported by strong fundamentals2025 Pullback Review & Consistent Income Trade Recommendations - Улправда
Why Arbutus Biopharma Corporation stock is seen as undervaluedProduct Launch & Low Drawdown Trading Strategies - Улправда
Hepatitis B Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Arbutus Biopharma, GSK/Ionis Pharma, Vir Biotech, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp - The Globe and Mail
Hepatitis B Market to Witness Promising Upswing by 2034, - openPR.com
Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN
Arbutus Biopharma (NASDAQ:ABUS) Shares Up 6%Still a Buy? - MarketBeat
Pharma Patent Trials Loom in 2026 for Wegovy, Covid-Vaccine Tech - Mintz
Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Why Arbutus Biopharma Corporation stock is rated strong buyEarnings Recap Summary & Fast Moving Market Watchlists - Улправда
ABUS (Arbutus Biopharma) OCF Margin % : -1,099.62% (As of Sep. 2025) - GuruFocus
Is Arbutus Biopharma Corporation stock ready for breakoutCEO Change & Reliable Entry Point Alerts - ulpravda.ru
Does Arbutus Biopharma Corporation stock trade at a discount to peersPortfolio Update Report & Weekly Watchlist of Top Performers - Улправда
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.4%What's Next? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 6.6%Should You Buy? - MarketBeat
BlackBarn Capital Partners LP Boosts Stock Position in Arbutus Biopharma Corporation $ABUS - MarketBeat
A Look at Arbutus Biopharma Corp (ABUS) Shares in the Recent Past Indicates Growth - setenews.com
Arbutus Biopharma Corp Discusses Ongoing Patent Litigation - TradingView — Track All Markets
[8-K] Arbutus Biopharma Corp Reports Material Event | ABUS SEC FilingForm 8-K - Stock Titan
Arbutus Biopharma Corporation $ABUS Shares Purchased by Two Seas Capital LP - MarketBeat
New Haven biotech names new CFO - hartfordbusiness.com
The time has not yet come to remove your chips from the table: Arbutus Biopharma Corp (ABUS) - setenews.com
Why global investors buy Arbutus Biopharma Corporation (I9DN) stockWeekly Trend Summary & Community Supported Trade Ideas - Newser
Can Arbutus Biopharma Corporation (I9DN) stock hold up in economic slowdown2025 Year in Review & Real-Time Stock Entry Alerts - Newser
Is Arbutus Biopharma Corporation (I9DN) stock a buy for dividend portfoliosPortfolio Value Report & Fast Moving Stock Trade Plans - Newser
Arbutus Biopharma (ABUS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How Arbutus Biopharma Corporation (I9DN) stock trades after earningsJuly 2025 Short Interest & Capital Efficiency Focused Strategies - Newser
Why Arbutus Biopharma Corporation (I9DN) stock could outperform next yearJuly 2025 Short Interest & Safe Capital Allocation Plans - Newser
Finanzdaten der Arbutus Biopharma Corp-Aktie (ABUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):